Daniel SW Tan
机构: National Cancer Centre Singapore
每年引用次数
引用次数
引用: 21,159
H-指数: 61
I10-指数 : 161
出版物: 486
Determinants of the Age of Myopia Onset in Singaporean Children
M. Dirani , D. M. Hornbeak , D. M. Hornbeak , Q. Fan
Investigative Ophthalmology & Visual Science 50 ( 13) 3950 -3950
2009
Correlation of the long-term neurological outcomes with completeness of surgical evacuation in spontaneous supratentorial intracerebral haemorrhage: a retrospective study.
D. K. S. Choy , D. Tan , P. H. Wu , T. T. Yeo
Singapore Medical Journal 51 ( 4) 320 -325
3
2010
P38.03 Immunohistochemical, Histologic and Genomic Characterisation of Early Stage Pulmonary Invasive Mucinous Adenocarcinoma
A. Takano , Q.S. Ng , K.H.T. Lim , M. Ang
Journal of Thoracic Oncology 16 ( 3)
2021
MA13.08 Genomic and Transcriptomic Features of Distinct Resistance Trajectories in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
A. Devanand , R. Nahar , A. Takano , A. Gogna
Journal of Thoracic Oncology 16 ( 3)
2021
P59.08 THOR: Multi-Ethnic, Open Access Thoracic Cancer Genomics Resource
A. Takano , K.H.T. Lim , W. Lim , E. Tan
Journal of Thoracic Oncology 16 ( 3)
2021
P76.46 First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
Q.S. Ng , M. Ang , W. Lim , E. Tan
Journal of Thoracic Oncology 16 ( 3)
2021
OA06.05 Molecular and Clinical Features Associated with Relapse in Early Stage EGFR-Mutated NSCLC: A Single Institution Knowledge Bank
A. Takano , Q.S. Ng , K.H.T. Lim , M. Ang
Journal of Thoracic Oncology 16 ( 3)
2021
FP14.10 Efficacy and Safety of Selpercatinib (LOXO-292) in East Asian Patients with RET Fusion-Positive NSCLC
Y. Ohe , M. Nishio , Y.J. Kim , V. Soldatenkova
Journal of Thoracic Oncology 16 ( 3)
2021
OA01.06 Randomised Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR Mutant NSCLC
A. Takano , A. Gogna , C.W. Too , N. Rohatgi
Journal of Thoracic Oncology 16 ( 3)
1
2021
P76.03 Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non–Small Cell Lung Cancer
A. Bearz , B. Hughes , M. Boyer , E. Felip
Journal of Thoracic Oncology 16 ( 3)
1
2021
P76.88 Real-World Data of Osimertinib in Patients with Metastatic EGFRm+ NSCLC who Progressed on First-Line EGFR TKIs
A. Takano , Q.S. Ng , K.H.T. Lim , M. Ang
Journal of Thoracic Oncology 16 ( 3)
2021
FP14.13 Molecular Characterisation and Clinical Outcomes in RET Rearranged Non-Small Cell Lung Cancer (NSCLC)
A. Takano , Q.S. Ng , K.H.T. Lim , M. Ang
Journal of Thoracic Oncology 16 ( 3)
2021
The lived experiences of community dwelling adults with Parkinson's disease towards exercise and participation in a rehabilitation trial
D. Tan , C. Tan , E.K. Tan , A. Mahfooza
Physiotherapy 101
2015
139PD: Lifetime incidence of brain metastases (BM) in EGFR-mutant (M+) lung cancer treated with first-line EGFR TKIs.
D.Z. Ng , W.L. Tan , W.S. Ong , E.M. Gan
Journal of Thoracic Oncology 11 ( 4)
1
2016
178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC
D. Tan , G. Liu , D.-W. Kim , M. Thomas
Journal of Thoracic Oncology 11 ( 4)
1
2016
OP3 Cost-effectiveness of epidermal growth-factor receptor mutation testing and first-line treatment with gefitinib for advanced non-small-cell lung cancer
G de Lima Lopes , J Segel , D Tan , Y Do
Ejc Supplements 9 ( 1) 2
3
2011
Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours
D. Tan , M. Ng , V. Subbiah , W. Messersmith
Annals of Oncology 29
7
2018
322PAssociation of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (SCC) in Singapore
P.Y. Fong , S. Acharyya , D.W. Lim , E.-H. Tan
Annals of Oncology 26
2015
419OEfficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) – results from ASCEND-2 and ASCEND-3
K. Park , D. Tan , M.-J. Ahn , C.-J. Yu
Annals of Oncology 26
4
2015
478TiPA phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease
J. Wolf , M. Hochmair , J.G. Kattan , M.-K. Ang
Annals of Oncology 26
2
2015